In a setback to GlaxoSmithKline (GSK), a legal adviser to the European Court of Justice suggested the drug maker may have restricted competition when it reached patent settlements with several generic companies that sought to market a version of the Paxil antidepressant.

Although not legally binding, the determination supports a decision made three years ago by the U.K. Competition and Markets Authority, which argued that between 2001 and 2004, Glaxo paid several generic companies more than $65 million to effectively delay the launch of lower-cost versions of its pill. The patent on the antidepressant, known as Seroxat in the U.K., expired in 1999.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy